The short version of Certificate of analysis fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-02-23. Anything still debated is marked as such rather than presented as settled.
Identity and purity are commonly assessed by reversed-phase high-performance liquid chromatography, with ultraviolet detection near 214 nanometers for the peptide backbone. Mass spectrometry, either electrospray or matrix-assisted laser desorption, confirms molecular mass and detects truncation or modification products. Amino acid analysis can verify composition. Because the sequence contains no strongly absorbing aromatic residue apart from phenylalanine, detection wavelengths are chosen carefully. Purity values above 95 percent are typical for research-grade material.
Quality documentation for research-grade peptide usually includes a certificate of analysis stating purity, identity, and residual counterion content. Batch-to-batch variation in purity and salt form is a recognized issue, and comparisons across suppliers require attention to the exact counterion, for example acetate versus trifluoroacetate. Sequence verification by tandem mass spectrometry provides stronger evidence than a single mass measurement. For any study reporting biological results, the analytical method and the measured purity should be stated explicitly. Independent verification of supplier claims is considered good practice.
Semax is supplied as a lyophilized powder that appears white to off-white. It dissolves readily in water, phosphate-buffered saline, and other aqueous media, which simplifies preparation of working solutions for laboratory use. The nasal products registered in Russia are dilute aqueous solutions, typically around 0.1 percent peptide by weight. Organic solvents are rarely necessary and can complicate handling. Because the peptide is hygroscopic, weighing should be performed quickly and with minimal exposure to ambient humidity.
The compound was developed in the 1980s at the Institute of Molecular Genetics in Moscow, where it emerged from research on short ACTH fragments and their effects on the central nervous system. Russian pharmaceutical listings describe it as a nootropic and neuroprotective agent, most often formulated as nasal drops. It is not a marketed medicine in the United States or the European Union, and no pharmacopoeial monograph covers it. Consequently, most published clinical experience with the substance originates from a small number of research centres, mainly in Russia and neighbouring countries.
Pharmacological accounts link semax to melanocortin signalling and to modulation of neurotrophic factor expression, particularly brain-derived neurotrophic factor and nerve growth factor. Much of this evidence comes from rodent studies using intranasal delivery, a route chosen because it allows peptides to reach the central nervous system with limited systemic exposure. Whether the same mechanisms operate in humans at comparable magnitude remains an open question. The precise receptor or receptors responsible for the reported behavioural and neuroprotective effects have not been conclusively identified.
| Property | Value | Notes |
|---|---|---|
| Typical purity | ≥95% by HPLC | Research-grade material |
| Detection wavelength | 214 nm | Peptide bond absorbance |
| Reconstitution medium | Sterile water or saline | Prepare fresh or aliquot immediately |
| Storage (solution) | -80 °C, single-use aliquots | Avoid repeated freeze-thaw cycles |
| Common salt form | Acetate or trifluoroacetate | Affects mass and solubility |
Claims about enhanced focus, memory, or mood in healthy people rest mostly on anecdotal reports and community discussion rather than on controlled data. It remains unclear whether any cognitive benefit observed in patients recovering from brain injury would extend to uninjured users. Dose-response relationships, long-term safety, and interactions with other drugs are not well characterized in the peer-reviewed literature. Questions about optimal route of administration and treatment duration likewise remain open.
Semax binds to melanocortin receptors and is thought to influence neuronal survival and plasticity rather than to act through the adrenal axis. Laboratory work has shown increased expression of brain-derived neurotrophic factor and nerve growth factor in treated tissue. Changes in c-Fos, a marker of neuronal activation, have also been reported. Because the peptide is rapidly degraded by peptidases, its effects are generally attributed to downstream signaling cascades rather than to sustained receptor occupancy.
Development is attributed to researchers at the Institute of Molecular Genetics in Moscow during the early 1980s, building on earlier Soviet work with ACTH fragments. Russian regulatory approval followed for intranasal use, and the compound has remained commercially available there for decades. Most published human data originate from Russian and, later, some Eastern European clinical reports, which are not always accessible in English translation. Outside that region the material is generally handled as a research chemical rather than a licensed medicine.
Regulatory status differs sharply between jurisdictions. In Russia the peptide is registered as a prescription nasal preparation, while agencies such as the United States Food and Drug Administration have not approved it for any indication. Products sold elsewhere are typically labeled for laboratory research only, and such labels shift responsibility for safe handling to the purchaser. Because the same name covers pharmaceutical-grade nasal drops and bulk research powder, identity and purity documentation becomes the main practical concern when comparing sources.
Semax is a synthetic seven-amino-acid peptide whose sequence extends the ACTH(4-10) fragment with a C-terminal proline-glycine-proline tripeptide. The commonly cited sequence is Met-Glu-His-Phe-Pro-Gly-Pro, giving a molecular formula near C37H51N9O10S and a molecular weight close to 813.9 g/mol. It belongs to the broader class of synthetic ACTH fragments studied for central nervous system effects rather than for adrenal steroid stimulation. In practice the material appears as a lyophilized white powder for laboratory work or as a dilute saline solution in clinical settings.
Material sold for laboratory use varies widely in stated purity and documentation. A certificate of analysis should list the analytical method, the column and detector used, and the observed purity value. Independent verification by an outside laboratory is the practical way to confirm identity when documentation is absent or internally inconsistent. Regulatory status differs by country, and a product legal in one jurisdiction may be unapproved or controlled in another.
Identity and purity of semax are established with reversed-phase high-performance liquid chromatography coupled to ultraviolet detection, usually at 214 nanometres. Mass spectrometry, most often electrospray ionisation in positive mode, confirms the molecular mass and reveals truncated sequences. Amino acid analysis and peptide mapping after enzymatic digestion provide additional structural confirmation. Laboratories typically report purity as the percentage area of the main peak, a figure that does not capture isomeric or oxidised variants unless the method resolves them.
Semax is a synthetic heptapeptide with the sequence Met-Glu-His-Phe-Pro-Gly-Pro. Its chain combines the first seven residues of corticotropin with a C-terminal proline-glycine-proline extension, a modification intended to slow enzymatic breakdown. The free peptide has a molecular mass near 813.9 daltons. It belongs to the class of ACTH-derived fragments studied for central nervous system activity rather than for adrenal steroid stimulation. This structural relationship to a natural hormone fragment is the usual starting point for describing the compound in the literature.
Development took place during the 1980s at institutes of the Russian Academy of Sciences, where peptide fragments of ACTH were screened for cognitive and neuroprotective effects. The compound received regulatory approval in Russia as a nasal preparation, marketed for conditions such as ischemic stroke, transient ischemic attacks, and optic nerve disorders. Registration in other countries has not followed. Most published clinical reports originate from a small number of Russian research groups, and independent replication outside that setting remains limited. The regulatory status therefore differs sharply between Russia and the rest of the world.
== Mechanism of action == Like other enediynes, kedarcidin chromophore comprises a core structure that forms destructive free radicals, as well as appendages that deliver this "warhead" to its DNA target. Thus, the general mechanism by which kedarcidin chromophore damages DNA is known; however, the details of this process—particularly the necessity of nucleophilic activation—have been disputed.
=== Solvent process === The process involves transesterification of sucrose and triglycerides under a basic condition at 90 °C. DMF was used as a solvent at first, but was later substituted with dimethyl sulfoxide or DMSO, which is less hazardous and cheaper. This process produces a mixture of sucrose monoesters and more substituted esters at about a 5:1 ratio.
== Treatment == The treatment aims to create an environment that allows skin to grow across an ulcer. In most cases, this requires finding and treating underlying venous reflux. The National Institute for Health and Care Excellence (NICE) recommends referral to a vascular service for anyone with a leg ulcer that has not healed within two weeks or anyone with a healed leg ulcer. Most venous ulcers respond to patient education, elevation of the foot, elastic compression, and evaluation (known as the Bisgaard regimen). Exercise together with compression stocking increases healing. There is no evidence that antibiotics, whether administered intravenously or by mouth, are useful. Silver products are also not typically useful, while there is some evidence of benefit from cadexomer iodine creams. There is a lack of quality evidence regarding the use of medical-grade honey for venous leg ulcers. The recommendations for dressings to treat venous ulcers vary between the countries. Antibiotics are often recommended to be used only if advised by the physician due to the emergence of bacterial resistance to antibiotics. This is an issue with venous ulcers as they tend to heal more slowly than acute wounds, for example. Natural alternatives that are suitable for long-term use exist on the market, such as honey and resin salve. These products are considered as Medical Devices in EU and the products have to be CE marked. Sugar has long been known for its effectiveness in wound treatment, notably through the use of honey or powdered sugar.
== Pharmacology == The drug potentiates the tropomyosin receptor kinases TrkA, TrkB, and TrkC with EC50Tooltip half-maximal effective concentration values of 382 nM, 295 nM, and ~330 nM, respectively. As a positive allosteric modulator of TrkA and TrkB, ACD856 potentiates the effects of brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF). In addition to the tropomyosin receptor kinases, ACD856 is also a similarly potent positive allosteric modulator of certain other receptor tyrosine kinases, including the insulin-like growth factor 1 receptor (IGF1R) and the fibroblast growth factor receptor 1 (FGFR1). However, its efficacies at the IGF1R and FGFR1 were much lower than at the TrkA, TrkB, and TrkC. In animals, ACD856 has been found to reverse scopolamine- and dizocilpine (MK-801)-induced memory impairment, to improve age-related memory deficits, and to have sustained antidepressant-like activity. It has also been reported to possess neuroprotective properties. In humans, the drug has been shown to cross the blood–brain barrier and to induce dose-dependent changes in electroencephalogram parameters. No significant tolerability or safety concerns have been identified in preclinical research or phase 1 clinical trials. The drug's clinical pharmacokinetics have been characterized and its elimination half-life is approximately 19 hours.
The GentleLys buffer employs synthetic nanodisc copolymers to gently disrupt the cell membrane, offering a milder alternative to conventional detergent-based lysis buffers. This gentle approach eliminates the need for harsh chemicals, creating an environment that preserves the native state of cellular proteins. Consequently, the proteins maintain their structural integrity and functionality, a marked departure from the denaturing effects of detergent-based buffers.
Sources: en.wikipedia.org
Beta-alanine decreases fatigue during high-intensity exercise by increasing the muscle carnosine concentration. Branched-chain amino acids, leucine, isoleucine and valine are commonly used for their muscle fueling properties and relief of post-workout soreness, often alongside other amino acids such as glutamine which are thought to have synergistic effects. Results from research have been mixed, and the dose contained in commercial pre-workout products is often less than an optimum effective dose. β-Hydroxy-β-methylbutyrate may sometimes be used as an ingredient in some products, though is prohibitively expensive for most commercial pre-workout blends. Arginine (sometimes as complexes like arginine alpha-ketoglutarate), is also commonly used as a nitric oxide precursor and supposed booster of growth hormone and IGF-1 release, though studies have shown limited benefits, and generally at higher doses than are present in typical pre-workout products. Ornithine or L-ornithine L-aspartate are sometimes used as an alternative or in addition to arginine, and have generally similar properties. Citrulline (sometimes as "watermelon extract") is used as an alternative or supplement to arginine, and is claimed to reduce post-exercise soreness. Agmatine is also often used as an alternative or supplement to arginine. Taurine is also a common ingredient in pre-workout, and can be used as a supplement taken alone. It is similar to creatine purportedly to aid muscle hypertrophy that increases strength, endurance, reduced muscle damage, and helps with a faster recovery.
=== January 2008 === In the third week of January 2008, the SENSEX experienced huge falls along with other markets around the world. On 21 January 2008, the SENSEX saw its highest ever loss of 1,408 points at the end of the session. The SENSEX recovered to close at 17,605.40 after it tumbled to the day's low of 16,963.96, on high volatility as investors panicked following weak global cues amid fears of a recession in US. The next day, the BSE SENSEX index went into a free fall. The index hit the lower circuit breaker in barely a minute after the markets opened at 10 am. Trading was suspended for an hour. On reopening at 10.55 am IST, the market saw its biggest intra-day fall when it hit a low of 15,332, down 2,273 points. However, after reassurance from the Finance Minister of India, the market bounced back to close at 16,730 with a loss of 875 points. Over the course of two days, the BSE SENSEX in India dropped from 19,013 on Monday morning to 16,730 by Tuesday evening or a two-day fall of 13.9%. Less than a month later, on 11 February 2008, the SENSEX lost 833.98 points, when Reliance Power fell below its IPO price in its debut trade after a high-profile public offer.
The functionality of a given protein is heavily dependent on its structure. Proteins reach this structure through the process of protein folding, which is facilitated by a variety of intra- and inter-molecular bonds. While much of the folding is driven by the formation of hydrogen bonds, covalent bonding of cysteine residues into disulfide bridges imposes constraints that stabilize particular conformations while preventing others from forming. As the bond energy of a covalent disulfide bridge is higher than the energy of a coordinate bond or hydrophobic interaction, greater numbers of disulfide bridges lead to higher energies required for protein denaturation. Disulfide bonds often serve to stabilize protein structures in the more oxidizing conditions of the extracellular environment. Within the cytoplasm, disulfide bonds may instead be reduced (i.e. in -SH form) to their constituent cysteine residues by thioredoxins. Many important cellular enzymes use prosthetic groups ending with sulfhydryl (-SH) moieties to handle reactions involving acyl-containing biochemicals: two common examples from basic metabolism are coenzyme A and alpha-lipoic acid. Cysteine-related metabolites homocysteine and taurine are other sulfur-containing amino acids that are similar in structure, but not coded by DNA, and are not part of the primary structure of proteins, take part in various locations of mammalian physiology. Two of the 13 classical vitamins, biotin and thiamine, contain sulfur, and serve as cofactors to several enzymes.
E + S ⇄ ES ⇄ ES* ⇄ EP ⇄ E + P When enzymes bind multiple substrates, such as dihydrofolate reductase, enzyme kinetics can also show the sequence in which these substrates bind and the sequence in which products are released. An example of enzymes that bind a single substrate and release multiple products are proteases, which cleave one protein substrate into two polypeptide products. Others join two substrates together, such as DNA polymerase linking a nucleotide to DNA. Although these mechanisms are often a complex series of steps, there is typically one rate-determining step that determines the overall kinetics of the entire process. This step may be a chemical reaction or a conformational change of the enzyme or substrates, such as those involved in the release of product(s) from the enzyme. Knowledge of the enzyme's structure is helpful in interpreting kinetic data. For example, the structure can suggest how substrates and products bind during catalysis; what changes occur during the reaction; and even the role of particular amino acid residues in the mechanism. Some enzymes change shape significantly during the mechanism; in such cases, it is helpful to determine the enzyme structure with and without bound substrate analogues that do not undergo the enzymatic reaction. Not all biological catalysts are protein enzymes: RNA-based catalysts such as ribozymes and ribosomes are essential to many cellular functions, such as RNA splicing and translation.
=== Medieval period === In the Golden age of the Islamic Caliphate (medieval time in Europe), a form of passport was the bara'a, a receipt for taxes paid. Border controls were in place to ensure that only people who paid their zakah (for Muslims) or jizya (for dhimmis) taxes could travel freely between different regions of the Caliphate; thus, the bara'a receipt was a "basic passport". In medieval Europe, passports were issued as early as the reign of Henry V of England to help his subjects prove who they were in foreign lands. The earliest reference to these documents is found in an act of Parliament, the Safe Conducts Act 1414 (2 Hen. 5. Stat. 1. c. 6). In 1540, granting travel documents in England became a role of the Privy Council of England, and it was around this time that the term "passport" was used. In 1794, issuing British passports became the job of the Office of the Secretary of State. The 1548 Imperial Diet of Augsburg required the public to hold imperial documents for travel, at the risk of permanent exile. During World War I, European governments introduced border passport requirements for security reasons, and to control the emigration of people with useful skills. These controls remained in place after the war, becoming a standard, though controversial, procedure. British tourists of the 1920s complained, especially about attached photographs and physical descriptions, which they considered led to a "nasty dehumanization". Beginning in the mid-19th century, the Ottoman Empire established quarantine stations on many of its borders to control disease.
Sources: en.wikipedia.org
Solid peptide is best kept frozen at about minus 20 degrees Celsius in a sealed container with desiccant. It should be allowed to reach room temperature before opening to prevent condensation. Repeated warming and cooling of the same vial is discouraged.
Reversed-phase liquid chromatography establishes purity, while mass spectrometry confirms molecular mass. The two techniques are normally used together. Retention time alone is not sufficient evidence of identity.
Different counterions change the mass per unit of peptide and can shift chromatographic behavior. Two samples of equal stated purity may therefore not be directly comparable. Reports should specify the counterion whenever quantitative comparisons are made.
It is described as a synthetic analogue of the ACTH(4–10) fragment, a short segment of adrenocorticotropic hormone. Its sequence differs from that fragment and includes two proline residues, which influence stability and behaviour in solution.